procarbazine (Rx)Brand and Other Names:Matulane

 
 
 

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

capsule

  • 50mg
more...

Hodgkin's Disease

Part of COPP, BEACOPP & MOPP regimens

2-4 mg/kg/day in single or divided doses for 7 days; increase dose by 4-6 mg/kg/day until maximum response obtained or WBC<4,000 cells/mm³ or plateletes<100,000 cells/mm³; reduce dosage to 1-2 mg/kg/day after maximum effect obtained 

Alternatively, 100 mg/m² PO qDay for 7-14 days of each 28 day cycle in combo with other antineoplastics 

Monitor: CBC

Glioma (Orphan)

Treatment of malignant glioma

Orphan indication sponsor

  • Sigma-Tau Pharmaceuticals, Inc; 9841 Washingtonian Blvd, Suite 500; Gaithersburg, MD 20878

Renal Impairment

Use caution; may result in increased toxicity if BUN above 40 mg/dL

Hepatic Impairment

Use caution; may result in increased toxicity if AST or ALT >1.6 ULN

Dosage Forms & Strengths

capsule

  • 50mg
more...

Hodgkin's Disease

50 mg/m² PO qDay for 7 days; increase to 100 mg/m²/day until maximum response obtained or leukopenia or thrombocytopenia observed 

Monitor: CBC

Hodgkin's Disease

Adjust for renal impairment if necessary

Part of COPP, BEACOPP & MOPP regimens

2-4 mg/kg/day in single or divided doses for 7 days; increase dose by 4-6 mg/kg/day until maximum response obtained or WBC<4,000 cells/mm³ or plateletes<100,000 cells/mm³; reduce dosage to 1-2 mg/kg/day after maximum effect obtained 

Alternatively, 100 mg/m² PO qDay for 7-14 days of each 28 day cycle in combo with other antineoplasticsMonitor: CBC 

Next

Interactions

Interaction Checker

procarbazine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Frequency Not Defined

            Neuropathy

            Neurotoxicity

            Nausea

            Vomiting

            Pleural effusion

            Myelosuppression

            Heinz bodies

            Hepatic dysfunction

            Impairment of fertility

            Previous
            Next

            Warnings

            Black Box Warnings

            The therapy should be given only by or under the supervision of a physician experienced in the use of potent antineoplastic drugs.

            Adequate clinical and laboratory facilities should be available to patients for proper monitoring of treatment.

            Contraindications

            Hypersensitivity

            Severe anemia, leukopenia, thrombocytopenia, bone marrow depression

            Cautions

            Discontnue if CNS S/S, hypersensitivity reaction, stomatitis, diarrhea, hemorrhage, hemolysis

            Discontinue if WBC <4000/mm³ &/or Plateletes <100,000/mm³

            Caution in hepatic/renal impairment

            Avoid alcohol, food high in tyramine

            Avoid pregnancy

            May cause infertility

            Has MAO inhibitor activity (potential for food and drug interactions)

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: D

            Lactation: Excreted in breast milk, do not nurse

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Methylhydrazine derivative; inhibits protein, DNA, RNA synthesis; may suppress mitosis and damage DNA directly

            Some MAOI activity

            Pharmacokinetics

            Half-life elimination: 1 hr

            Peak Plasma Time: 1 hr

            Metabolism: liver, kidney

            Excretion: Urine

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.